News Ampyra Helps MS Patients Not Only Walk Better, But Feel Better Too, Study Reports Ampyra Helps MS Patients Not Only Walk Better, But Feel Better Too, Study Reports by Joana Fernandes, PhD | November 2, 2016 Share this article: Share article via email Copy article link Results from a Phase 2 clinical trial showed that treatment with Ampyra (prolonged-release fampridine) brought bothĀ physical and psychological benefits to patients with multiple sclerosis (MS). These findings,Ā fromĀ the MOBILE study (NCT01597297), were published under the title, āProlonged-Release Fampridine Treatment Improved Subject-Reported Impact Of Multiple Sclerosis: Item-Level Analysis Of The MSIS-29,ā in the Journal of the Neurological Sciences. Oral Ampyra is currently the only drug approved in the U.S. to specifically treat walking impairment in MS, a common disability in patients, after two Phase 3 clinicalĀ trials showed that the treatment resulted in consistent increases in walking speed. Treatment benefits, however, may extend beyond walking. āRecent studies have demonstrated that the benefits of [Ampyra] may extend beyond walking speed,ā the researchersĀ wrote. āImprovements in arm function, physical and cognitive fatigue, mood and quality of life were reported in [Ampyra]ātreated subjects with MS, who showed improvements in walking ability ā¦ The psychological benefits of [Ampyra] were also reported in the ENABLE study.” Researchers analyzed the results of the MOBILE study, which expanded upon the ENABLE trialĀ (NCT01480076). MOBILE evaluated the physical (walking ability) and psychological (well-being) health outcomes of subjects with progressing or relapsing MS, usingĀ the self-reportedĀ Multiple Sclerosis Impact Scale (MSIS-29) that measures both those outcomes. PeopleĀ assigned to the Ampyra treatment (68 patients) group received 10 mg twice daily for up to 24 weeks, and the control group (64 patients)Ā received a placebo. Ampyra treatment resulted in greater improvements from baseline in the MSIS-29 physical and psychological impact subscales, with differences of 89 percent and 148 percent in mean score reduction from baseline after 24 weeks, compared to placebo, respectively (lower scores represent improvement on these scales). More Ampyra-treatedĀ patients also achieved mean improvements in 16 of 20 physical and 6 of 9 psychological measures compared to those placebo after 24 weeks. TheĀ Ampyra group also showedĀ improvements in the 12-item Multiple Sclerosis Walking Scale (MSWS-12) at 24 weeks. In fact,Ā patients whoseĀ MSWS-12 walking ability improved (by at least 8 points) were also seen to strengthenĀ physically onĀ theĀ MSIS-29 scale, showing an 82 percent improvement from their self-reported baseline (study start) scores at week 12, and 97 percent by the study’s end. āThe results of the MOBILE study suggest that the benefits of [Ampyra] extend beyond walking speed and also improve the subject-perceived physical and psychological impact of MS versus placebo, particularly in those who show clinically meaningful increases in walking ability,ā the authors concluded. Studies with larger groups to confirm the positive effects of Ampyra are currently ongoing. Print This Page About the Author Joana Fernandes, PhD Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology. Tags Ampyra
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients